Cantor Fitzgerald, L. P. Poseida Therapeutics, Inc. Transaction History
Cantor Fitzgerald, L. P.
- $656 Million
- Q1 2024
A detailed history of Cantor Fitzgerald, L. P. transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Cantor Fitzgerald, L. P. holds 75,205 shares of PSTX stock, worth $221,102. This represents 0.04% of its overall portfolio holdings.
Number of Shares
75,205
Previous 50,205
49.8%
Holding current value
$221,102
Previous $168,000
42.26%
% of portfolio
0.04%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding PSTX
# of Institutions
93Shares Held
38.1MCall Options Held
255KPut Options Held
62K-
Pentwater Capital Management LP Naples, FL5.98MShares$17.6 Million0.2% of portfolio
-
Black Rock Inc. New York, NY4.95MShares$14.6 Million0.0% of portfolio
-
Boxer Capital, LLC San Diego, CA4.48MShares$13.2 Million0.74% of portfolio
-
Silverarc Capital Management, LLC3.6MShares$10.6 Million3.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.37MShares$9.92 Million0.0% of portfolio
About Poseida Therapeutics, Inc.
- Ticker PSTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 85,775,600
- Market Cap $252M
- Description
- Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...